AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, multicenter phase II clinical study. The aim is to evaluate the safety,
tolerability, and anti-tumor activities of AK104(a PD-1/CTLA-4 bispecific antibody) in
MSI-H/dMMR locally advanced gastric adenocarcinoma and colorectal cancer during the
perioperative period.Eligible patients will receive AK104 for three cycles before surgery and
at most 6 months after surgery. The primary endpoint is the pathological complete response
rate.